Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5699415 | Clinical Oncology | 2010 | 9 Pages |
Abstract
In this UK network, about half of patients were considered for chemoradiation, but only 18% received it. Survival and treatment-related toxicity are consistent with data from other chemoradiation trials and in our series chemoradiation was tolerated better than chemotherapy alone. This supports the view that 'consolidation' chemoradiation is a viable treatment option that should be considered in selected patients with locally advanced non-metastatic pancreatic cancer.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
E. Hudson, C. Hurt, D. Mort, A.E. Brewster, N. Iqbal, G. Joseph, T.D.L. Crosby, S. Mukherjee,